Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it;s very thin..few more big hits and this can move to .01..IMO
moving up nicely here..Bid $0.0017 Ask $0.0023
now: Bid $0.0017 Ask $0.0018
ATWOQ:
Bid $0.0012 Ask $0.0013
we dnt know yet..
Float is only 13 million so it should move easily..
we saw some volume today so thought it;s better to release it early rather than wait till 5 min before the close..
yes this is the one that was suppose to be release 5 min before the close..
One more pick coming afterhours !! so be ready for that..
----Official Q Team pick------
ATWOQ @ .0017
Float is only 13 million
Company Info:
21 is a leading digital content marketplace for the professional creative community. Through SuperStock (www.superstock.com), a21 provides images distinguished by the quality of
their photographers and the attention to the customer experience. a21 provides a whole new level of image access to the best photographers, artists, photography agencies and customers in the stock image business.
SS:
Estimated Market Cap
$62,219 as of Sept 2, 2010
Outstanding Shares
88,883,587 as of Aug 14, 2008
Authorized Shares
100,000,000 as of Mar 31, 2004
Float (shares)
13,099,254 as of Mar 31, 2004
Number of Shareholders of Record
2,000 as of Mar 31, 2008
Agreed..Smart investors will load AVNR tomorrow if there will be a big sell off..I would personally wont mind adding more shares @ $2.70..GLTA
QCOR ($9.78)has a PDUFA date of September 11
nice jump today...lets close at .18
i am not the CEO of this company..there are lots of other stocks to play..you win some and you lose some..no need to keep crying..learn how to move on with the life..
BIOD ($3.84) moving up nicely here..
Thanks
I will whisper it Friday A/H..so be ready !! :)
Dnt worry our next pick will be bigger then this..:)
AVNR ($2.91) came back strongly here..
I added few shares as well @ 2.93..cant resist this price..
Good Morning guys..
yes looking good..it can move easily if we get some news..IMO
Hey "Q" Team....Next pick will be alerted @10am Wednesday....this one is the low floater so make sure you guys dnt miss this one..GLTA
Good Morning guys..hope everybody is having fun...
BMOD I like the potential here..could be easily .50+ again with Phase II results..
Why dnt you try and buy/sell shares to see if it;s halted or not..just dnt assume things ...
Good Morning guys !!
ALXA ($2.99) doing well today..
Is there any Merger news coming ???
ALXA (2.80) nice bounce..it should move higher..IMO..GLTA
Biomoda (BOMD)@.16 - Allowed Patent in Canada
ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
Allowed by the Canadian Intellectual Property Office, Canadian patent application 2,429,526, “Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine,” is similar to Biomoda’s U.S. patent 6,838,248, which was issued in 2005. Foreign equivalents are now effective in Canada, Mexico, Japan and Australia and are pending in Europe.
“With the World Health Organization reporting more than 5 million tobacco-related deaths every year, lung cancer mortality is clearly a global issue,” said Biomoda President John Cousins. “Protecting our intellectual property at the international level is the first step toward a global strategy for the commercialization and marketing of the CyPath® assay for early detection of lung cancer.”
The 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine, or TCPP, is the foundation for several Biomoda product lines and medical diagnostics. The company is completing data analysis for the pilot clinical trial of its first product, an in-vitro test for the detection of early-stage lung cancer, in which study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath® assay. The company anticipates that results from the pilot study will provide the foundation for a pivotal clinical study leading to submission to the U.S. Food and Drug Administration (FDA) for approval of the commercial sale of Biomoda’s technology.
Biomoda is seeking FDA approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only. The company is also pursuing strategies to enter the European market, including filing for approval of a CE mark.
About Biomoda
Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, N.M.
Biomoda (BOMD)@.16 - Allowed Patent in Canada
ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
Allowed by the Canadian Intellectual Property Office, Canadian patent application 2,429,526, “Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine,” is similar to Biomoda’s U.S. patent 6,838,248, which was issued in 2005. Foreign equivalents are now effective in Canada, Mexico, Japan and Australia and are pending in Europe.
“With the World Health Organization reporting more than 5 million tobacco-related deaths every year, lung cancer mortality is clearly a global issue,” said Biomoda President John Cousins. “Protecting our intellectual property at the international level is the first step toward a global strategy for the commercialization and marketing of the CyPath® assay for early detection of lung cancer.”
The 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine, or TCPP, is the foundation for several Biomoda product lines and medical diagnostics. The company is completing data analysis for the pilot clinical trial of its first product, an in-vitro test for the detection of early-stage lung cancer, in which study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath® assay. The company anticipates that results from the pilot study will provide the foundation for a pivotal clinical study leading to submission to the U.S. Food and Drug Administration (FDA) for approval of the commercial sale of Biomoda’s technology.
Biomoda is seeking FDA approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only. The company is also pursuing strategies to enter the European market, including filing for approval of a CE mark.
About Biomoda
Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, N.M.
Thanks buddy..hoping ALXA will be good too..run up to PDUFA date..IMO
BMOD @ .18 - Great news today..Phas II results coming soon too
Biomoda Allowed Patent in Canada
The company is completing data analysis for the pilot clinical trial of its first product, an in-vitro test for the detection of early-stage lung cancer, in which study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath® assay. The company anticipates that results from the pilot study will provide the foundation for a pivotal clinical study leading to submission to the U.S. Food and Drug Administration (FDA) for approval of the commercial sale of Biomoda’s technology.
Great news !!
Market is down but SOMX is flying hard..Glad I picked up few shares yesterday..GLTA
oh ok Thanks
whats your opinion your SOMX ??..they have a Silenor launch coming Next Month and rumour of buyout..
ALXA @ 2.82..Great..
ALXA ($2.72) nice close..